Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-14T01:59:47.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of an open-label, phase Ib/II study of surufatinib in combination with tislelizumab for patients with advanced solid tumors.
    Difference
    0.1%
    Check dated 2024-06-06T16:04:24.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Participation Criteria 6 on the webpage has been updated to include specific eligibility criteria for different cohorts of patients with advanced solid tumors, such as adenocarcinoma of the colon or rectum, neuroendocrine tumors, small cell lung cancer, and other conditions. The change reflects the detailed requirements for inclusion and exclusion in the clinical trial, focusing on factors like prior treatments, performance status, and specific tumor characteristics.
    Difference
    32%
    Check dated 2024-05-22T08:37:49.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Summary
    The value 'Go to the classic website' has been updated to 'Site Map' on the webpage, indicating a change in the type of intervention possibly related to medical and healthcare publications and documentation.
    Difference
    1.0%
    Check dated 2024-05-01T15:18:47.000Z thumbnail image

Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.